Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma

By sjmartinez • August 28, 2024

Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma. Transplant Cell Ther. 2024 Aug 24:S2666-6367(24)00619-5. doi: 10.1016/j.jtct.2024.08.018. Epub ahead of print. PMID: 39187161.

Tags: axi-cel, CAR T-cell therapy, Hematology/Oncology, LBCL, Publications

Related Posts

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial

Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia[...]

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Zhu AX, Qin S, Vogel A. Tislelizumab versus Sorafenib[...]